← Russell 3000 cross-section

IRD Opus Genetics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$322m
Revenue TTM
$10m
Net income TTM
$-108m
Free cash flow
Composite score
Sector rank
#2621

Valuation

P / E
EV / EBITDA
EV / sales
27.2
FCF yield
Earnings yield vs 10-yr
-38.15pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,091.8%
EBITDA margin
-512.9%
ROE
828.7%
ROIC
Revenue growth
-36.1%

Insider activity, last 90 days

Net open-market
$-0.09m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total issuance expenses, including sales agent fees and legal and accounting expenses, were $0.1 million for the three and six months ended June 30, 2026. Opus Genetics, Inc. Financial Operations Overview License and collaborations revenue License and collaborations revenue to date was derived from a one-time, non-refundable payment related to a license transfer, an additional milestone payment and reimbursement of expenses earned under the Viatris License Agreement, and to a much lesser degree, from license agreements with BioSense Global LLC (“BioSense”) and Processa Pharmaceuticals, Inc. …Opus Genetics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →